Centipede Venom Tops Morphine

The substance targets the same ion channel that's mutated in people who don't feel pain.

kerry grens
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, YASUNORI KOIDEAn alteration in a sodium ion channel can leave people completely indifferent to pain, making the channel an appealing target for analgesic development. In a report published in the Proceedings of the National Academy of Sciences this week (September 30), researchers characterize a newly discovered component of centipede venom that inhibits this particular sodium channel, NaV1.7, and works even better than morphine to dampen pain in rodents. “Centipedes worked out hundreds of millions of years ago the easiest way to catch prey was to paralyze them by blocking their NaV channel,” Glenn King, one of the authors of the study, told ABC. “We're just lucky that of the nine NaV channels in humans, it hit the one we were after.”

King, a researcher at the University of Queensland, said that other attempts to bind the NaV1.7 channel blocked other sodium channels and produced untoward effects. But King and his colleagues found that the venom-derived peptide was much more selective for 1.7 than for other sodium ion channels. And it showed no negative impacts on heart rate, blood pressure, or motor function. The centipede peptide was also more potent than morphine in a chemically induced pain assay in mice, and was just as effective as the narcotic in relieving pain induced by acid or heat.

Of course, a number of studies will have to validate the safety and efficacy of the drug before it could be used to treat pain in humans. Already, several venom-derived peptides ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • kerry grens

    Kerry Grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide